LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Abierto

SectorSanidad

2.69 5.08

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.55

Máximo

2.71

Métricas clave
By Trading Economics
Ingresos	4.1M -5.7M
Empleados	34
EBITDA	3.1M -6.8M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+678.21% upside

Dividendos
By Dow Jones
Próximas Ganancias	9 jun 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-113M 276M
Apertura anterior	-2.39
Cierre anterior	2.69

Noticias sobre sentimiento de mercado

By Acuity

50%

161 / 344 Clasificación en Healthcare

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 jun 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 jun 2026, 15:41 UTC

Principales Movimientos del Mercado

American Battery Shares Jump on Energy Department Victory

8 jun 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 jun 2026, 23:37 UTC

Charlas de Mercado

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 jun 2026, 23:25 UTC

Charlas de Mercado

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 jun 2026, 23:25 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jun 2026, 21:57 UTC

Adquisiciones, fusiones, absorciones

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 jun 2026, 21:56 UTC

Adquisiciones, fusiones, absorciones

Salesforce Agrees to Buy m3ter

8 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

8 jun 2026, 19:22 UTC

Charlas de Mercado

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 jun 2026, 19:01 UTC

Charlas de Mercado

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 jun 2026, 18:52 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

8 jun 2026, 18:52 UTC

Charlas de Mercado

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 jun 2026, 18:17 UTC

Charlas de Mercado

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 jun 2026, 17:32 UTC

Charlas de Mercado

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 jun 2026, 17:29 UTC

Charlas de Mercado

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 jun 2026, 17:29 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 jun 2026, 16:55 UTC

Adquisiciones, fusiones, absorciones

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 jun 2026, 16:54 UTC

Adquisiciones, fusiones, absorciones

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 jun 2026, 16:40 UTC

Charlas de Mercado

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 jun 2026, 16:31 UTC

Charlas de Mercado

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 jun 2026, 16:27 UTC

Charlas de Mercado

Mexican Inflation Seen Easing in May -- Market Talk

8 jun 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 jun 2026, 16:03 UTC

Adquisiciones, fusiones, absorciones

Orange Bought Stake From Lorca

8 jun 2026, 16:01 UTC

Adquisiciones, fusiones, absorciones

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 jun 2026, 16:01 UTC

Adquisiciones, fusiones, absorciones

Orange Acquires 100% Ownership of MasOrange

8 jun 2026, 15:58 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jun 2026, 15:58 UTC

Charlas de Mercado

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 jun 2026, 15:55 UTC

Charlas de Mercado

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 jun 2026, 15:41 UTC

Charlas de Mercado

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

678.21% repunte

Estimación a 12 Meses

Media 20 USD 678.21%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

161 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.